Your session is about to expire
← Back to Search
Study Summary
This trial tests a new cancer drug in patients with solid tumors. It checks safety & effectiveness.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had anti-PD-L1 therapy in the last 12 weeks or anti-PD-1 therapy in the last 4 weeks.I've been cancer-free for a year, except for minor skin cancers or in situ cancers.I have received standard treatment for my cancer in its advanced stages.I am willing to have biopsies before and during treatment if needed.I have an active autoimmune disease or a history of one.I have had or currently have lung inflammation not caused by an infection.I have been treated with more than one anti-PD-1 or anti-PD-L1 therapy.I have brain metastases that haven't been treated.I have never been treated with anti-ILT4 antibody.My cancer has returned, spread, or is very advanced, but it's not a brain tumor.I have not had blood clots in the past 6 months.
- Group 1: CDX-585
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent does CDX-585 present a hazard to patients?
"There is limited to no data that exists on the safety and efficacy of CDX-585, so it has been assigned a score of 1."
Are candidates able to join this research endeavor at present?
"Affirmative. Clinicaltrials.gov verifies that this clinical trial, originally posted on May 11th 2023, is actively enrolling participants. At present, 130 patients from one location are needed to complete the study."
What is the current participation rate of this clinical research?
"Correct. According to clinicaltrials.gov, this trial was first posted on May 11th 2023 and is still actively recruiting participants. The study requires 130 individuals from one site for full participation."
What are the desired outcomes of this experiment?
"This clinical trial, which has a 6 month duration as its temporal parameter, intends to determine the maximum tolerated dose of CDX-585 and select it for further evaluation. The safety and tolerability of this drug will be assessed via CTCAE v5.0 while secondary objectives include evaluating overall survival patterns and the duration of response in patients who meet measure criteria."
Share this study with friends
Copy Link
Messenger